Forty-Year Long-Term Outcome After Endoscopic and Open Surgery for Esthesioneuroblastoma in Consideration of Prognostic Factors

Koch M, Balk M, Schlaffer SM, Agaimy A, Iro H, Müller SK (2025)


Publication Language: English

Publication Type: Journal article

Publication year: 2025

Journal

Book Volume: 17

Article Number: 343

Journal Issue: 3

DOI: 10.3390/cancers17030343

Abstract

Background: The objective of this study was to compare results after endoscopic (ES) and open surgery (OpS) for esthesioneuroblastoma over a 40-year period. Methods: In a retrospective study, patients who had undergone ES and OpS for esthesioneuroblastoma with curative intent were included. The following outcome parameters were compared after ES and OpS: epidemiologic, clinical (including known tumor classifications), histopathologic, therapeutic (resection state, adjuvant therapy), and development of recurrences. Crude survival and Kaplan–Meier 10 y, 20 y, and 35 y actuarial survival were calculated. Results: Between 1981 and 2021, 15 patients were operated with ES and 28 with OpS. Advanced-stage tumors were significantly more often treated using OpS. For all other parameters, there were no other significant differences between ES and OpS. After ES, the 35 y OS, DSS, and DFS were 48.1%, 100%, and 55.9%, respectively. After OpS, they were 40.5%, 77.5%, and 35.3%. Conclusions: ES is an effective approach in esthesioneuroblastoma, even in the long-term course over decades, if the appropriate indication compared to OpS is respected.

Authors with CRIS profile

How to cite

APA:

Koch, M., Balk, M., Schlaffer, S.-M., Agaimy, A., Iro, H., & Müller, S.K. (2025). Forty-Year Long-Term Outcome After Endoscopic and Open Surgery for Esthesioneuroblastoma in Consideration of Prognostic Factors. Cancers, 17(3). https://doi.org/10.3390/cancers17030343

MLA:

Koch, Michael, et al. "Forty-Year Long-Term Outcome After Endoscopic and Open Surgery for Esthesioneuroblastoma in Consideration of Prognostic Factors." Cancers 17.3 (2025).

BibTeX: Download